Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Efficacy by Baseline Demographic and Disease Characteristics in the Phase 3 POETYK PSO-1 and PSO-2 Trials. J of Skin [Internet]. 2023 Jul. 17 [cited 2025 Apr. 7];7(4):s219. Available from: https://skin.dermsquared.com/skin/article/view/2225